Live Breaking News & Updates on Research Award For Fondation De France

SparingVision Expands Novel Ocular Disease Pipeline with Acquisition of GAMUT Therapeutics
GAMUT
rod-cone dystrophies such as retinitis
pigmentosa
rod-cone dystrophies
today
-
Paris,
202
1 - SparingVision (the Company ), a genomic medicines company developing vision saving treatments for ocular diseases, today announces it has entered into a definitive agreement to acquire GAMUT Therapeutics ( GAMUT ), a biotechnology company pioneering a unique gene-independent approach to treat the later stages of rod-cone dystrophies such as retinitis pigmentosa ( RP ). The acquisition, subject to legal formalities and approval by shareholders of both companies, will be paid mostly in new SparingVision shares and is expected to close in Q2 2021. Further financial terms of the transaction are not disclosed. ....

Frankfurt Am Main , United States , France General , Olivia Manser , Amber Fennell , Deniz Dalkara , Kostenloser Wertpapierhandel , Max Planck , Davide Salvi , Priit Piip , Nathalie Trepo , Research Award For Fondation De France , Biotherapeutics Department , Ministry Of Research , Technology Review Innovators , Nanomedicine Development Center , Foundation Fighting Blindness , Paris Vision Institute , Sparingvision The Company , University Of Louis Pasteur , Consilium Strategic Communications , Chief Executive Officer , Institut De La Vision , Advent France , Operating Partner , Advent France Biotechnology ,